Welcome to our dedicated page for Prestige Consmr Healthcare news (Ticker: PBH), a resource for investors and traders seeking the latest updates and insights on Prestige Consmr Healthcare stock.
Prestige Consumer Healthcare Inc. markets, sells, manufactures and distributes over-the-counter consumer healthcare products to retail outlets in the U.S. and Canada, Australia and other international markets. Its brand portfolio spans women’s health, pain relief, eye care, oral care, motion sickness, gastrointestinal, pediatric, lice treatment, ear care, rehydration, and nasal and sinus care, including Monistat, Summer’s Eve, Clear Eyes, TheraTears, DenTek, Dramamine, Fleet, Chloraseptic, Compound W, Little Remedies, Nix, Debrox, Hydralyte and Fess.
Company news commonly covers fiscal earnings releases, investor presentations, brand and category performance, supply conditions for key products such as Clear Eyes, share repurchase activity, capital-structure updates, material agreements and completed portfolio actions such as the Pillar5 Pharma eye care supplier acquisition.
Prestige Consumer Healthcare (NYSE: PBH) reported its fiscal year 2024 results with $277.0 million in Q4 revenue and $1,125.4 million for the full year, a slight 0.2% increase from the previous year. Q4 net income was $49.5 million, a significant improvement from the previous year's net loss of $240.6 million. The company's leverage ratio was reduced to 2.8x, below its long-term target. The Board authorized a new $300 million share repurchase program. For fiscal 2025, Prestige anticipates a 1% organic revenue growth and an EPS range of $4.40 to $4.46. Ongoing supply chain issues, particularly in eye care products, affected Q4 performance but are expected to improve mid-2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.